Published in Dtsch Arztebl Int on March 05, 2010
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Dangerous errors in the diagnosis and treatment of bony tuberculosis. Dtsch Arztebl Int (2009) 3.61
Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med (2008) 5.81
Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest (2012) 3.44
Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest (2009) 3.24
Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med (2010) 2.67
Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge. Dtsch Arztebl Int (2010) 2.36
Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J (2013) 2.20
Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J (2013) 2.12
Cost-effectiveness of treating latent tuberculous infection: a step towards elimination? Int J Tuberc Lung Dis (2013) 1.58
Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot.TB test in contact investigations for tuberculosis. Chest (2008) 1.39
Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet (2007) 1.34
Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest (2007) 1.21
Value of flexible bronchoscopy in the pre-operative work-up of solitary pulmonary nodules. Eur Respir J (2012) 0.97
Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J (2012) 0.93
Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis. Chest (2004) 0.93
To repeat or not to repeat-that is the question!: Serial testing of health-care workers for TB infection. Chest (2012) 0.83
Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial. Anticancer Res (2004) 0.82
Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002‒2011. Euro Surveill (2015) 0.80
HIV-prevalence in tuberculosis patients in Germany, 2002-2009: an estimation based on HIV and tuberculosis surveillance data. PLoS One (2012) 0.80
Tuberculosis: are we making it incurable? Eur Respir J (2013) 0.78
Prolonged isoniazid prevention in HIV-positive children: hepatotoxicity is not a major problem. Int J Tuberc Lung Dis (2013) 0.75
Treatment of MDR-TB: is hepatotoxicity a problem? Int J Tuberc Lung Dis (2012) 0.75
[High incidence and resistance rates in Eastern Europe. Is tuberculosis coming back?]. MMW Fortschr Med (2004) 0.75
[On the article by Rüdinger Meyer: Latent tuberculosis, Discussion on therapy in the USA. Pneumologie 2006; 60: 2]. Pneumologie (2006) 0.75
Emerging and re-emerging infectious diseases: a continuous challenge for Europe. Eur Respir J (2012) 0.75